{"success":true,"data":{"pressRelease":{"id":"164016","rtpr_id":"nGNX9xxg3J-20261008","ticker":"AGIO","exchange":"NASDAQ","all_tickers":["AGIO"],"title":"Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET","author":"Globe Newswire","published_at":"2026-10-08T11:00:00.705Z","article_body":"CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals,\nInc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on\ndelivering innovative medicines for patients with rare diseases, today\nannounced the company will host a conference call and live webcast on\nThursday, November 5, 2026, at 8:00 a.m. ET to report its third quarter 2026\nfinancial results and business highlights.\n\nThe live webcast will be accessible on the Investors section of the\ncompany’s website (www.agios.com) under the “Events & Presentations”\ntab. A replay of the webcast will be available on the company’s website\napproximately two hours after the event.\n\nAbout Agios: Fueled by Connections to Transform Rare Diseases™\nAt Agios, our vision is to redefine the future of rare disease treatment.\nFueled by connections, we build trusted partnerships with communities –\ncollaborating to develop and deliver innovative medicines that have the\npotential to transform lives. With a foundation in hematology, we combine\nbiological expertise with real-world insights to advance a growing pipeline of\nrare disease medicines that reflect the priorities of the people we serve.\nAgios is a commercial-stage biopharmaceutical company headquartered in\nCambridge, Massachusetts. To learn more, visit www.agios.com and follow us on\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=7k3ta0qkP0ls4uLNCq63G7lJWYfLY_6u_HF-TbOl7ZLb5WwHb_9RX1TLqsMn2GHuJk2l5MLsAdlIzlQMfsO1HQbds0mjRYGF2BoPbLDOi7w=)\nand X\n(https://www.globenewswire.com/Tracker?data=QeV6MUPjejC5au8cRNj0s263SBMfLdCJZspZhonlW23Qzj8xENgxSp_3qFsE6Bq3uSpTjbmLabzwWQx4v1_SCQ==).\n\nAvailable Information about Agios \nTo achieve broad dissemination, Agios may disclose information to the public\nthrough a variety of disclosure channels including press releases, SEC\nfilings, and public conference calls and webcasts. Some of the information\ndistributed through these disclosure channels may be considered material\ninformation. Investors and others should note that Agios plans to use its\nwebsite (www.agios.com) as a distribution channel to announce and give notice\nof Agios’ upcoming events and presentations (including, but not limited to,\npresentations at medical or healthcare conferences). Such information, which\nmay be deemed material, will be available on the Investors section of the\ncompany’s website under the “Events & Presentations” tab. In addition,\nyou may sign up to automatically receive email alerts about Agios’ upcoming\nevents and presentations (“Calendar Alerts”) by visiting the “Email\nAlerts” option under the “IR Resources” tab of the Investors section of\nthe company’s website and submitting your email address.\n\nContacts:\nInvestor Contact\nMorgan Sanford, Vice President, Investor Relations\nAgios Pharmaceuticals\nmorgan.sanford@agios.com\n\nMedia Contact\nEamonn Nolan, Senior Director, Corporate Communications\nAgios Pharmaceuticals\neamonn.nolan@agios.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c7d64dad-71c8-47cc-a58d-c93a49ce8f01)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9xxg3J-20261008","title":"Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET","author":"Globe Newswire","ticker":"AGIO","created":"2026-10-08T11:00:00.705Z","tickers":["AGIO"],"exchange":"NASDAQ","article_body":"CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals,\nInc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on\ndelivering innovative medicines for patients with rare diseases, today\nannounced the company will host a conference call and live webcast on\nThursday, November 5, 2026, at 8:00 a.m. ET to report its third quarter 2026\nfinancial results and business highlights.\n\nThe live webcast will be accessible on the Investors section of the\ncompany’s website (www.agios.com) under the “Events & Presentations”\ntab. A replay of the webcast will be available on the company’s website\napproximately two hours after the event.\n\nAbout Agios: Fueled by Connections to Transform Rare Diseases™\nAt Agios, our vision is to redefine the future of rare disease treatment.\nFueled by connections, we build trusted partnerships with communities –\ncollaborating to develop and deliver innovative medicines that have the\npotential to transform lives. With a foundation in hematology, we combine\nbiological expertise with real-world insights to advance a growing pipeline of\nrare disease medicines that reflect the priorities of the people we serve.\nAgios is a commercial-stage biopharmaceutical company headquartered in\nCambridge, Massachusetts. To learn more, visit www.agios.com and follow us on\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=7k3ta0qkP0ls4uLNCq63G7lJWYfLY_6u_HF-TbOl7ZLb5WwHb_9RX1TLqsMn2GHuJk2l5MLsAdlIzlQMfsO1HQbds0mjRYGF2BoPbLDOi7w=)\nand X\n(https://www.globenewswire.com/Tracker?data=QeV6MUPjejC5au8cRNj0s263SBMfLdCJZspZhonlW23Qzj8xENgxSp_3qFsE6Bq3uSpTjbmLabzwWQx4v1_SCQ==).\n\nAvailable Information about Agios \nTo achieve broad dissemination, Agios may disclose information to the public\nthrough a variety of disclosure channels including press releases, SEC\nfilings, and public conference calls and webcasts. Some of the information\ndistributed through these disclosure channels may be considered material\ninformation. Investors and others should note that Agios plans to use its\nwebsite (www.agios.com) as a distribution channel to announce and give notice\nof Agios’ upcoming events and presentations (including, but not limited to,\npresentations at medical or healthcare conferences). Such information, which\nmay be deemed material, will be available on the Investors section of the\ncompany’s website under the “Events & Presentations” tab. In addition,\nyou may sign up to automatically receive email alerts about Agios’ upcoming\nevents and presentations (“Calendar Alerts”) by visiting the “Email\nAlerts” option under the “IR Resources” tab of the Investors section of\nthe company’s website and submitting your email address.\n\nContacts:\nInvestor Contact\nMorgan Sanford, Vice President, Investor Relations\nAgios Pharmaceuticals\nmorgan.sanford@agios.com\n\nMedia Contact\nEamonn Nolan, Senior Director, Corporate Communications\nAgios Pharmaceuticals\neamonn.nolan@agios.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c7d64dad-71c8-47cc-a58d-c93a49ce8f01)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-08T11:00:00.786908313Z","server_sent_at_ms":1791457200786},"received_at":"2026-10-08T11:00:00.836Z","source_url":null},"analysis":{"id":"152451","press_release_id":"164016","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Agios Pharmaceuticals announced it will report third quarter 2026 financial results on Thursday, November 5, 2026, at 8:00 a.m. ET via conference call and live webcast.\n\nThe webcast will be available on the Investors section of the company's website, with a replay posted roughly two hours after the event.\n\nNo financial results or business updates were disclosed in this scheduling announcement.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine earnings-date scheduling notice for Agios Q3 2026 results -- no results content."},"keyFigures":{},"namedEntities":{"people":[{"name":"Morgan Sanford","role":"Vice President, Investor Relations"},{"name":"Eamonn Nolan","role":"Senior Director, Corporate Communications"}],"products":[],"companies":[{"name":"Agios Pharmaceuticals, Inc.","ticker":"AGIO"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a boilerplate earnings-date announcement with no results, figures, or guidance. It only schedules the Q3 2026 call for November 5."},"tickerRelevance":{"others":[],"primary":"AGIO"},"globalImportance":8,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"hasResults":false,"tickerTier":"mid-cap biotech","eventGravity":"earnings-date-notice"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Agios Pharmaceuticals announced it will report third quarter 2026 financial results on Thursday, November 5, 2026, at 8:00 a.m. ET via conference call and live webcast.\n\nThe webcast will be available on the Investors section of the company's website, with a replay posted roughly two hours after the event.\n\nNo financial results or business updates were disclosed in this scheduling announcement.","key_figures":{},"named_entities":{"people":[{"name":"Morgan Sanford","role":"Vice President, Investor Relations"},{"name":"Eamonn Nolan","role":"Senior Director, Corporate Communications"}],"products":[],"companies":[{"name":"Agios Pharmaceuticals, Inc.","ticker":"AGIO"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T11:00:12.452Z","global_importance":8,"audience_relevance":20,"importance_components":{"hasResults":false,"tickerTier":"mid-cap biotech","eventGravity":"earnings-date-notice"}},"durationMs":4860,"modelName":"glm-5.3-flashx"}}